-+ 0.00%
-+ 0.00%
-+ 0.00%

Adocia says Sanofi’s exclusive M1Pram partnership talks right expires

PUBT·07/03/2026 16:01:31
Listen to the news
Adocia says Sanofi’s exclusive M1Pram partnership talks right expires
  • Adocia’s three-year exclusive negotiation right granted to Sanofi for an M1Pram partnership has expired.
  • Adocia retained full global rights to M1Pram; the exclusivity was granted in July 2023 for EUR 10 million.
  • Development of M1Pram has been paused while the company reassesses its prospects as type 1 diabetes treatments evolve.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adocia SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260703470130) on July 03, 2026, and is solely responsible for the information contained therein.